Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation.
暂无分享,去创建一个
M. Cazzola | C. Pascutto | F. Passamonti | L. Arcaini | M. D. Della Porta | E. Rumi | D. Pietra | M. Lazzarino | E. Boveri | C. Elena | L. Vanelli | Cecilia Del Curto
[1] A. Tefferi,et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients , 2007, Leukemia.
[2] W. Vainchenker,et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. , 2007, Blood.
[3] J. Spivak,et al. Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression. , 2006, Blood.
[4] M. Cazzola,et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders , 2006, Cancer.
[5] François Girodon,et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.
[6] G. Thomas,et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. , 2006, Blood.
[7] A. Tefferi,et al. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. , 2006, Blood.
[8] M. Cazzola,et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. , 2006, Blood.
[9] T. Vulliamy,et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. , 2006, Blood.
[10] E. Montserrat,et al. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution , 2006, Leukemia.
[11] H. Lodish,et al. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] R. Levine,et al. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera , 2005, British journal of haematology.
[13] M. Cazzola,et al. Leukemic transformation of polycythemia vera , 2005, Cancer.
[14] Mario Cazzola,et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.
[15] T. Barbui,et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. , 2005 .
[16] A. Gallamini,et al. High telomerase activity in granulocytes from clonal polycythemia vera and essential thrombocythemia. , 2005, Blood.
[17] R. Mesa,et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. , 2005, Blood.
[18] M. Cazzola,et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. , 2004, The American journal of medicine.
[19] D. Stockton,et al. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. , 2003, Blood.
[20] S. Nakao,et al. Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. , 2002, Experimental hematology.
[21] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[22] E. Montserrat,et al. Myelofibrosis with myeloid metaplasia following essential thrombocythaemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients , 2002, British journal of haematology.
[23] A. Tefferi. Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.
[24] T. Brümmendorf,et al. Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. , 2000, Blood.
[25] G. Barosi,et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia , 1999, British journal of haematology.
[26] P. Wiernik,et al. Anticipation in familial plasma cell dyscrasias , 1998, British journal of haematology.
[27] D. Catovsky,et al. Anticipation in familial chronic lymphocytic leukaemia , 1998, Leukemia.
[28] J. Laszlo,et al. Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.
[29] E. Goode,et al. Anticipation in familial leukemia. , 1996, American journal of human genetics.
[30] S. Folstein,et al. Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease. , 1995, American journal of human genetics.
[31] J. Laszlo,et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. , 1986, Seminars in hematology.
[32] J. Goldberg,et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. , 1986, Seminars in hematology.